Clinical trials
Genomics clinical trials
Below are recruiting genomics clinical trials, each written for real people, not researchers. We’re tracking 270 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07357207Enrolling by invitation
Video-immunotherapy for advanced breast cancer
This trial tests if a video-based immunotherapy approach can help treat locally advanced breast cancer. It is designed for people who can communicate in Turkish and are comfortable playing video games as part of their treatment.
Izmir, BalcovaAges 18 years+ - NCT07358026Recruiting
Early pregnancy study: health before conception
This study follows women and their partners before pregnancy to understand how health before conception affects early development. It is for people planning a pregnancy who are generally healthy.
ChiguayanteAges 18–40 - NCT07356583Recruiting
Neonatal enterovirus infections in Italy
This study looks at enterovirus infections in newborn babies admitted to intensive care, focusing on one type called echovirus 11. It aims to better understand the virus and how it affects babies to improve care.
Pavia, LombardyAges 1 day–4 weeks - NCT07328373Recruiting
Depression Relapse Predictors Study
This trial looks at brain and genetic markers to understand why depression returns. It is for people with major depression who are not currently taking medication.
IstanbulAges 18–65 - NCT07317193Recruiting
Genetic causes of adult bile duct disease
This study looks for new genes that might cause abnormal liver test results or specific bile duct diseases in adults, when standard testing hasn't found a clear cause. It also uses healthy blood donors as a comparison group.
Milan, MilanoAges 18–65 - NCT04510129Recruiting
Cancer biospecimen collection study for immunotherapy patients
This study collects samples (like tissue biopsies and imaging information) from people with certain cancers who are starting anti–PD-1/PD-L1 immunotherapy. It helps researchers gather material to study how these treatments work.
San Francisco, CaliforniaAges 18 years+ - NCT06635954Recruiting
Blood test to predict response to immunotherapy
This study is testing a blood test (Episwitch CiRT®) that looks at your DNA to see if it can predict whether you will respond to a type of immunotherapy called PD-(L)-1 checkpoint inhibitors. The goal is to see if this test is accurate across many different types of cancer.
Norwich, ConnecticutAges 18 years+ - NCT07288632Recruiting
Lung cancer gene test and blood clot risk study
This study looks at whether certain gene profiles in advanced lung cancer affect the risk of blood clots. It may help doctors better understand and prevent clots in people starting new cancer treatment.
Perugia, PerugiaAges 18 years+ - NCT07291037RecruitingPhase 3
Comparing a new drug to standard chemo for advanced lung cancer
This trial tests a new drug called datopotamab deruxtecan against a standard chemotherapy (docetaxel) for people with a certain type of advanced lung cancer (non-squamous non-small cell lung cancer) that has already been treated. The new drug targets a protein called TROP2 found on cancer cells, which may help slow or stop the cancer's growth.
Chandler, ArizonaAges 18 years+ - NCT06803784Recruiting
Bioproducts in body fluids for early brain disease detection
This study is looking for proteins in blood and other body fluids that could help detect brain diseases like Parkinson's, Alzheimer's, and ALS early. It aims to improve diagnosis and future treatments.
Pozzilli, ItalyAges 20 years+ - NCT06717243Recruiting
Study on gene markers in lung cancer for treatment resistance
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
New York, New YorkAges 18–85 - NCT07282912RecruitingPhase 2
Extra treatment for certain digestive cancers with undetectable ctDNA
This trial tests if adding extra local treatments (like surgery or radiation) to usual care can improve outcomes for people with certain advanced digestive cancers that have spread to a limited number of sites. You may be eligible if your cancer has responded well to at least 4 months of therapy and your ctDNA (a sign of cancer in the blood) is undetectable.
New Haven, ConnecticutAges 18–80 - NCT05332561RecruitingPhase 2
Personalized treatment after surgery for early breast cancer
This Phase 2 study checks whether adding a personalized (biomarker-matched) medicine after standard chemotherapy and surgery lowers the risk of breast cancer coming back. Your study drug choice depends on tumor test results (from your tumor’s genetics and immune markers).
Heidelberg, Baden-WurttembergAges 18 years+ - NCT07277387Recruiting
Predicting complications in high-risk fever with low white blood cells
This trial studies whether proteins in your blood can predict complications when you have a fever and very low white blood cells after cancer treatment. It aims to help doctors choose the best antibiotics early on.
Barcelona, BarcelonaAges 18 years+ - NCT06894628Recruiting
Genomics and extreme radiation for recurrent prostate cancer
This study looks at how well a very short course of high-dose radiation works for prostate cancer that has come back after surgery. It aims to learn if genetics can help predict who benefits most from this type of radiation.
RomaAges Any age - NCT07250204Recruiting
Testing nipple discharge to tell benign from malignant breast disease
This study uses a blood test and a sample of nipple discharge to see if it can help doctors tell the difference between non-cancerous and cancerous conditions in the breast ducts. It aims to find a better way to diagnose intraductal disease without needing surgery right away.
Wuhan, HubeiAges 18 years+ - NCT07249112Recruiting
Genomic study of metabolic fatty liver disease
This study aims to understand the genetic factors behind metabolic fatty liver disease (MASLD) by comparing patients with advanced liver scarring or liver cancer to healthy blood donors. It may help doctors better predict and treat the disease in the future.
Milan, MilanoAges 18–90 - NCT07242352RecruitingPhase 3
Comparing elacestrant to standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.
Mannheim, Baden-WurttembergAges 18 years+ - NCT05530096Recruiting
Genetic test to find minimal residual myeloma in remission
This study tests a genetic technology (ClonoSeq-based) to detect very small amounts of multiple myeloma that may remain after treatment. It may help doctors better track how well treatment is working and predict how the disease responds over time.
Montreal, QuebecAges 18 years+ - NCT06912828Recruiting
Genes and diet for IBS
This trial is studying whether your genes can predict how well a special diet will help your IBS symptoms. If you have moderate to severe IBS and no other diet-related conditions, you may be able to take part.
AthensAges 18–65 - NCT06926127Recruiting
Genomic study for rare and genetic diseases
This study aims to use advanced genetic testing to better understand rare and genetic diseases. It may help find a diagnosis or guide personalized care for you or your child.
Rome, LazioAges 1 minute–90 years - NCT07201038Recruiting
Fast whole genome sequencing for childhood cancer
This trial uses a rapid type of genetic testing (whole genome sequencing) to look at the DNA of children and young adults with cancer. The goal is to better understand each person's cancer and potentially guide treatment decisions.
CambridgeAges birth–24 years - NCT07187063Recruiting
Using urine tests to reduce checkups for bladder cancer
This trial tests whether monitoring urine tumor DNA can safely reduce how often patients need invasive cystoscopy checkups after initial treatment for non-muscle invasive bladder cancer.
Burlington, MassachusettsAges 18 years+ - NCT06346418Recruiting
Maternal genes and Beckwith-Wiedemann syndrome risk study
This study looks at how a mother's genes and chemical changes to DNA (called epimutations) may increase the risk of having a child with Beckwith-Wiedemann syndrome or affect a woman's ability to get pregnant and carry a baby to term. It aims to find genetic clues that could help explain these reproductive challenges.
MilanAges 18 years+
Hear when a new Genomics trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for genomics?
- Yes. Clin2 currently lists 270 recruiting genomics studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a genomics trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a genomics trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.